Skip to main content
TipRanks
Go Ultimate75% OFF

Fcpr Biotechnology Fund Insider Profile

4 Followers

Fcpr Biotechnology Fund, Ten Percent Owner at SCYNEXIS, holds 295.08K shares in SCYNEXIS (Ticker: SCYX). Most recently, Fcpr Biotechnology Fund Bought 245,077 shares of SCYNEXIS on May 08, 2014 for an estimated value of $7.30K.

Fcpr Biotechnology Fund's Trading History

SCYX
SCYNEXIS
May 08, 2014Ten Percent OwnerInformative Buy7.30K$858.67K
SCYX
Insider Shares: 295.08K (2.12%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
May 08, 2014Informative Buy$500.00K50,000$10.00+7.10%
May 08, 2014Informative Buy$7.30K245,077$0.02+7.10%

You May Also Like

Fcpr Biotechnology Fund insider profile FAQ

What is the percentage of profitable transactions made by Fcpr Biotechnology Fund?
The percentage of profitable transactions made by Fcpr Biotechnology Fund is 100%.
What is the average return per transaction made by Fcpr Biotechnology Fund?
The average return per transaction made by Fcpr Biotechnology Fund is 7.10%.
What stocks does Fcpr Biotechnology Fund hold?
Fcpr Biotechnology Fund holds: SCYX stocks.
What was Fcpr Biotechnology Fund’s latest transaction?
Fcpr Biotechnology Fund’s latest transaction was an Informative Buy of $7.30K.
What was Fcpr Biotechnology Fund's most profitable transaction?
Fcpr Biotechnology Fund’s most profitable transaction was an Informative Buy of SCYX stock on May 8, 2014. The return on the trade was 7.10%.
What is Fcpr Biotechnology Fund's role in SCYNEXIS?
Fcpr Biotechnology Fund's role in SCYNEXIS is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.